A clinical trial of avapritinib versus regorafenib (Stivarga®) for people with advanced GIST that has progressed following first-line treatment with imatinib (Gleevec®) and one or two additional treatment regimens (third-line or fourth-line GIST).
Texas Oncology is focused on one thing: helping their patients fight cancer and blood disorders. This singular focus gives them specialized expertise in today’s most effective treatments.
Dallas, Texas Clinical Trial Location
OSU – Texas Oncology
3410 Worth St Suite 400,
Dallas, TX 75246